Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report

Khalid Al-Baimani; Harman S. Sekhon; Paul Wheatley-Price

doi:10.1016/j.ctrc.2015.03.001

Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report

Khalid Al-Baimani, Harman S. Sekhon, Paul Wheatley-Price^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.

Original language	English
Pages (from-to)	6-9
Number of pages	4
Journal	Cancer Treatment Communications
Volume	4
DOIs	https://doi.org/10.1016/j.ctrc.2015.03.001
Publication status	Published - 2015
Externally published	Yes

Keywords

ALK
NSCLC
Outcome
Relapse
Stage one

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ctrc.2015.03.001

Cite this

@article{49a88be9950f40c3b677a034346f95cf,

title = "Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report",

abstract = "Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.",

keywords = "ALK, NSCLC, Outcome, Relapse, Stage one",

author = "Khalid Al-Baimani and Sekhon, {Harman S.} and Paul Wheatley-Price",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",

year = "2015",

doi = "10.1016/j.ctrc.2015.03.001",

language = "English",

volume = "4",

pages = "6--9",

journal = "Cancer Treatment Communications",

issn = "2213-0896",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years

T2 - Case report

AU - Al-Baimani, Khalid

AU - Sekhon, Harman S.

AU - Wheatley-Price, Paul

PY - 2015

Y1 - 2015

N2 - Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.

AB - Introduction: About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC. Presentation of case: Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later. Discussion: It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis. Conclusion: This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.

KW - ALK

KW - NSCLC

KW - Outcome

KW - Relapse

KW - Stage one

UR - http://www.scopus.com/inward/record.url?scp=84947902007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947902007&partnerID=8YFLogxK

U2 - 10.1016/j.ctrc.2015.03.001

DO - 10.1016/j.ctrc.2015.03.001

M3 - Article

AN - SCOPUS:84947902007

SN - 2213-0896

VL - 4

SP - 6

EP - 9

JO - Cancer Treatment Communications

JF - Cancer Treatment Communications

ER -

Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this